Anna Suk-Fong Lok (Chinese: 駱淑芳) is a gastroenterologist who studied in Hong Kong and moved to the United States in 1992.
She is a Professor of Medicine at the University of Michigan in Ann Arbor and helped the World Health Organization (WHO) and American Association for the Study of Liver Diseases (AASLD) develop guidelines for medical professionals and recommendations for the general public on who should be treated and how treatments should be administered to persons with hepatitis B infections.
Lok obtained a medical degree from the University of Hong Kong and then completed her training in hepatology at the Royal Free Hospital in London, UK under the direction of Dame Sheila Sherlock.
She has also been at the forefront of research on the effects of chemotherapy and antiviral therapy for hepatitis B, utilizing grants from the National Institutes of Health in Bethesda, Maryland and Veterans Health Administration in Washington, D.C.[1] Lok was instrumental in helping the WHO and the AASLD develop guidelines for medical professionals and recommendations for the general public on who should be treated and how treatments should be administered to persons with hepatitis B infections.
[1] According to the annual ISI Web of Knowledge list published by Thomson Reuters, she has been one of the most cited scientific researchers since 2009.